• KAFM
  • Contact us
  • E-Submission
ABOUT
ARTICLE CATEGORY
BROWSE ARTICLES
AUTHOR INFORMATION

Articles

Original Article

Association between phase angle and albuminuria in Korean adults aged 40 years or older: a cross-sectional study of the 9th Korea National Health and Nutrition Examination Survey (2022–2023)

Published online: September 7, 2026

Department of Family Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea

*Corresponding Author: Yohwan Yeo Tel: +82-31-8086-2390, Fax: +82-31-8086-2709, E-mail: yohwan@hallym.or.kr
• Received: October 27, 2025   • Revised: May 1, 2026   • Accepted: May 24, 2026

© 2026 The Korean Academy of Family Medicine

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 982 Views
  • 13 Download
  • Background
    Phase angle (PhA), derived from bioelectrical impedance analysis, reflects cellular health and membrane integrity and is reduced in chronic diseases. Albuminuria is an early marker of endothelial and microvascular injury and predicts renal and cardiovascular diseases. This study aimed to investigate the association between PhA and albuminuria in Korean adults aged 40 years or older.
  • Methods
    We conducted a cross-sectional analysis of data from the 9th Korea National Health and Nutrition Examination Survey (2022–2023). After excluding participants younger than 40 years of age, those with diabetes, elevated serum creatinine levels, and those with missing data, 3,283 adults (1,495 men and 1,788 women) were included. Whole-body PhA at 50 kHz was used as the independent variable. Albuminuria was defined as a urine albumin-to-creatinine ratio of ≥30 mg/g. Survey-weighted, sex-stratified multivariate logistic regression models were adjusted for age, lifetime smoking, drinking frequency in the previous year, hypertension status, body mass index, glycated hemoglobin, low- and high-density lipoprotein cholesterol, triglycerides, serum creatinine, blood urea nitrogen, high sensitivity C-reactive protein, and skeletal muscle mass index.
  • Results
    Albuminuria was identified in 7.0% of the participants (7.2% of men and 6.9% of women). In women, each 1° increase in PhA was associated with substantially lower odds of albuminuria (adjusted odds ratio, 0.47; 95% confidence interval, 0.26–0.86). In men, the relationship showed a J-shaped pattern, with the lowest risk at mid-range PhA values and a marked increase at higher values; both linear and quadratic PhA terms were significant.
  • Conclusion
    In Korean adults, PhA showed sex-specific associations with albuminuria, with an inverse association in women and a J-shaped association in men. As a noninvasive and widely available measure, PhA could potentially serve as a supplementary tool for identifying individuals at risk for early renal microvascular injury.
Bioelectrical impedance analysis (BIA) is a noninvasive, simple, and portable method for estimating body composition by applying an alternating current through the body and resolving the measured whole-body impedance into resistance (R) and reactance (Xc) [1]. Phase angle (PhA) is derived from the reactance (Xc) and resistance (R) values obtained by BIA using the equation arctan (Xc/R)×(180/π) [1,2]. PhA is considered a reliable indicator of cellular health and membrane integrity [3,4]. Reduced PhA values have been observed in various chronic diseases, including obesity, cancer, liver cirrhosis, chronic obstructive pulmonary disease, and in patients undergoing hemodialysis [5-9].
Albuminuria is a well-established biomarker of cardiovascular and renal disease risk in adults [10,11]. It often manifests as an early sign of endothelial dysfunction and microvascular injury, arising from increased glomerular permeability caused by inflammatory and oxidative stress within the renal microcirculation [12,13]. Clinically, the presence of albuminuria indicates early renal damage and serves as an independent predictor of cardiovascular disease and mortality [10,11]. Findings from large population-based cohorts have shown that even low-grade albuminuria is associated with higher risks of cardiovascular events, mortality, and progressive renal dysfunction [10,11].
In metabolic disorders, such as type 2 diabetes, PhA values are generally lower than those in healthy individuals [14]. In patients with type 2 diabetes, PhA has demonstrated stronger associations with micro- and macrovascular complications than the triglyceride-glucose index, and higher PhA values have been linked to a lower prevalence of microalbuminuria, suggesting its potential role as a marker of microvascular injury [15].
However, evidence for this association in the general population remains limited. Therefore, this study aimed to investigate the association between PhA and albuminuria among adults aged 40 years or older in the general population, using data from the 9th Korea National Health and Nutrition Examination Survey (KNHANES) (KNHANES IX-1 and IX-2, 2022–2023).
Ethics statement
This study analyzed data from the 9th KNHANES. The 9th KNHANES was conducted in accordance with the guidelines provided by the Korea Disease Control and Prevention Agency (KDCA). The 9th KNHANES was approved by the Institutional Review Board of the KDCA (No. 2018-01-03-4C-A, 2022-11-16-R-A). Because the KNHANES dataset is publicly available and fully anonymized, this study was exempted from review by the Institutional Review Board of Hallym University Dongtan Sacred Heart Hospital, and the requirement for informed consent was waived (No. 2025-07-017).
Subjects
This study used data from the 9th KNHANES (KNHANES IX-1 and IX-2), which was conducted by the KDCA between January 2022 and December 2023 [16]. A total of 13,194 participants were initially included in the survey.
After excluding participants with missing survey weights (n=1,344), Individuals aged <40 years (n=3,855), those with diabetes (n=843), and those with abnormal serum creatinine levels (81 men and 70 women) were excluded. Serum creatinine was measured by a kinetic colorimetric assay (Jaffe method) using the CREJ2 reagent on a Cobas 8000 analyzer (Roche). According to the manufacturer’s instructions (Roche Diagnostics, 2019), the normal ranges were 0.7 to 1.2 mg/dL for men and 0.5 to 0.9 mg/dL for women [17]. In this study, participants with serum creatinine levels exceeding the upper normal limit (i.e., >1.2 mg/dL for men and >0.9 mg/dL for women) were excluded because elevated creatinine reflects impaired renal function.
We also excluded individuals with missing data for major variables or other covariates (n=3,718). Among the 3,718 excluded participants, 2,670 individuals were excluded because of missing data on the primary independent or dependent variables (PhA, urinary albumin, or urinary creatinine), whereas 1,048 individuals were excluded solely because of missing data for minor covariates. After applying the exclusion criteria, 3,283 adults (1,495 men and 1,788 women) were included in the present analysis (Figure 1).
Individuals with diabetes were excluded because diabetic nephropathy is the strongest confounding factor for albuminuria, which could obscure the independent association between PhA and early renal microvascular injury. Conversely, given the high prevalence of hypertension in the general adult population aged 40 years or older, excluding individuals with hypertension would severely compromise the representativeness of the primary care population. Therefore, individuals with hypertension were included, and hypertension status was adjusted for as a covariate in the multivariable models.
Variables

Phase angle

Body composition was assessed using a multi-frequency bioelectrical impedance analyzer (InBody 970, InBody Co. Ltd.). The measured parameters included fat-free mass, muscle mass (excluding bone minerals), fat mass, total body water, and whole-body PhA at 50 kHz. Whole-body PhA was derived from measurements obtained from the right side of the body (right arm, trunk, and right leg). Individuals with implanted cardiac devices (e.g., pacemakers and implantable cardioverter-defibrillators) and pregnant women were excluded. Whole-body PhA was used as the independent variable in this study.

Albuminuria

Urinary creatinine and albumin levels were measured using a Cobas 8000 analyzer (Roche). Urinary creatinine was determined using a kinetic colorimetric assay (Jaffe method), and urinary albumin was measured using an immunoturbidimetric assay. Albuminuria was calculated as the urinary albumin to creatinine ratio (UACR) (mg/g). Participants with a UACR <30 mg/g were classified as normal, whereas those with a UACR ≥30 mg/g were defined as having albuminuria [18]. The presence of albuminuria (defined as a UACR ≥30 mg/g) was used as the dependent variable in this study.
Statistical analysis
The participants were classified into the albuminuria and normal groups. Continuous variables are presented as means±standard deviation, and categorical variables are presented as counts and percentages. Between-group differences were assessed using the survey-weighted t-test for continuous variables and the survey-weighted chi-square test for categorical variables.
All analyses were performed using R software ver. 4.5.1 (R Foundation for Statistical Computing). Sampling weights were constructed by averaging the year-specific weights (wt_bia for 2022 and wt_itvex for 2023) to account for the combined multiyear dataset. These scaled weights, along with the strata (kstrata) and primary sampling units, were applied to reflect the complex multistage probability sampling design of the KNHANES.
As preliminary analyses suggested different patterns of association between PhA and albuminuria according to sex, subsequent analyses were stratified by sex. In women, survey-weighted multivariate logistic regression analysis was performed using PhA as a continuous independent variable. In men, because the initial linear model did not adequately capture the nonlinear pattern, both the linear and squared terms of PhA were included as independent variables in the survey-weighted multivariate logistic regression model to account for the observed J-shaped association. To further evaluate the nonlinear relationship between PhA and albuminuria in men, a multivariate logistic regression model, including both the linear and quadratic terms of PhA, was utilized as the primary analytical approach. Furthermore, to support these findings and evaluate the model fit, a restricted cubic spline (RCS) regression with four knots was performed as a sensitivity analysis. Model fit was evaluated using McFadden’s pseudo-R2. All regression models were adjusted for age, lifetime cigarette smoking history, drinking frequency in the previous year, hypertension status, body mass index (BMI), glycated hemoglobin (HbA1c), lipid profile (low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, and triglycerides), renal function markers (serum creatinine and blood urea nitrogen), inflammatory marker (high sensitivity C-reactive protein), and skeletal muscle mass index. Statistical significance was defined as a two-sided P-value of <0.05.
Baseline characteristics by albuminuria status and sex
A total of 3,283 participants (1,495 men and 1,788 women aged ≥40 years) were analyzed, of whom 230 (7.0%) had albuminuria (107 men, 7.2%; 123 women, 6.9%). The distribution of PhA showed distinct patterns between the groups. Among the 1,495 male participants, the mean PhA was 5.81°±0.67° in the nonalbuminuria group and 5.59°±0.91° in the albuminuria group (P=0.060). In contrast, among the 1,788 female participants, the mean PhA was significantly higher in the non-albuminuria group (4.91°±0.53°) compared to those with albuminuria (4.71°±0.60°, P=0.001).
Participants of both sexes with albuminuria were significantly older than those without. In men, the mean age was 62.50±12.57 years in the albuminuria group compared with 55.85±11.03 years in the non-albuminuria group (P<0.001). Similarly, women with albuminuria were a mean age of 62.12±11.87 years old compared with 57.48±11.13 years old among women without albuminuria (P<0.001).
Albuminuria was associated with a markedly higher rate of hypertension in both men and women. Among men with albuminuria, only 27.7% were normotensive compared with 62.2% of those without albuminuria, and the prevalence of uncontrolled hypertension was more than double (37.1% vs. 16.4% in men without albuminuria, P<0.001). A similar pattern was observed in women; 46.1% of women with albuminuria were normotensive compared with 68.2% of those without albuminuria, whereas uncontrolled hypertension was present in 27.0% of women with albuminuria compared with 12.0% of women without albuminuria (P<0.001). Women with albuminuria also had a higher prevalence of prediabetes. More than half (56.9%) of the women with albuminuria were classified as prediabetic compared with 41.6% of the non-albuminuric women (P=0.005). Furthermore, the frequency of alcohol consumption differed significantly according to albuminuria status in women (P=0.010).
Several laboratory measurements differed between the albuminuria groups. Men with albuminuria had a higher mean HbA1c level (5.56%±0.37% vs. 5.48%±0.32% in non-albuminuric men, P=0.036) and higher blood urea nitrogen (15.98±4.22 mg/dL vs. 14.87±3.82 mg/dL, P=0.015). In contrast, their mean LDL cholesterol level was lower (109.75±33.23 mg/dL vs. 121.49±35.93 mg/dL, P=0.002) in the albuminuria group. Among women, those with albuminuria had significantly lower HDL cholesterol levels on average (56.92±12.67 mg/dL vs. 61.66±15.23 mg/dL, P<0.001) and slightly higher HbA1c (5.55%±0.33% vs. 5.48%±0.33%, P=0.039) than women without albuminuria (Table 1).
Phase angle and albuminuria in women
In women, PhA was inversely associated with the presence of albuminuria. In the unadjusted analysis, each 1° increase in PhA corresponded to 51% lower odds of albuminuria (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.32–0.73; P<0.001). This association remained significant after adjusting for potential confounders: the adjusted OR was 0.47 (95% CI, 0.26–0.86; P=0.015). In addition to PhA, uncontrolled hypertension was the only independent factor associated with albuminuria in women. Women with uncontrolled hypertension had markedly higher odds of albuminuria (adjusted OR, 2.50; 95% CI, 1.45–4.28; P<0.001), whereas no other covariates (including age, BMI, HbA1c, or lipid levels) showed significant associations in the multivariable model (Table 2).
Phase angle and albuminuria in men
In men, the adjusted quadratic model suggested a possible J-shaped association between PhA and albuminuria. After multivariable adjustment, including a quadratic term for PhA, both the linear and quadratic PhA terms were significant, indicating a J-shaped association (PhA term: adjusted OR, 0.05; 95% CI, 0.004–0.60; PhA2 term: OR, 1.34; 95% CI, 1.05–1.71; both P<0.05). In the fully adjusted model with PhA modeled as a linear term only, no significant association was observed (adjusted OR, 1.16; 95% CI, 0.66–2.04; P=0.599); a quadratic term was therefore added. To address the potential instability of the quadratic model (owing to limited events per variable [EPV]), a RCS regression with four knots was performed. The overall Wald test confirmed a significant nonlinear J-shaped association between PhA and the risk of albuminuria in men (P=0.049). As shown in the RCS curve (Figure 2), the predicted probability of albuminuria reached its nadir at a PhA of approximately 5.0° to 6.0°. Beyond this inflection point, the probability began to increase substantially at higher PhA values.
Apart from PhA, age and blood pressure status were significant factors in men. Men with hypertension had an increased risk; those with uncontrolled hypertension had nearly 4-fold higher odds of albuminuria (adjusted OR, 3.82; 95% CI, 2.10–6.94; P<0.001), and even men with controlled hypertension had roughly double the odds compared with normotensive men (OR, 2.08; 95% CI, 1.15–3.76; P=0.015) (Table 3). The model fit indicators (McFadden’s pseudo-R2) for the final adjusted models were 0.1319 and 0.0762 for men and women, respectively.
This study analyzed data from 3,283 Korean adults aged ≥40 years who participated in the 9th KNHANES (2022–2023). Participants with diabetes or elevated serum creatinine levels were excluded to better examine the association between PhA and albuminuria in adults. We found that PhA was associated with albuminuria with notable sex-specific differences.
In women, our findings are in line with those of previous studies showing a protective association between PhA and microalbuminuria among female patients with diabetes, suggesting that PhA may reflect renal microvascular function as a marker of cellular integrity [15]. The biological rationale for this association is supported by previous studies demonstrating that a lower PhA reflects reduced cell membrane stability and intracellular water content, which are frequently observed in states of inflammation and oxidative stress [19,20]. These physiological alterations may be associated with endothelial dysfunction, which may increase glomerular permeability and facilitate albumin leakage even before overt renal disease develops. In men, the association between PhA and albuminuria followed a J-shaped pattern. We hypothesized that extremely high PhA values in men, which are strongly correlated with peak skeletal muscle mass, may be associated with overnutrition or high dietary protein intake. These factors may contribute to glomerular hyperfiltration and subsequent early renal microvascular injury. Furthermore, sex-specific hemodynamic stress and vascular stiffness may explain why this pattern was not observed in women.
Our study differs from prior research in several key aspects. First, by using the most recent nationally representative data and focusing on a strictly defined cohort without diabetes and with preserved renal function, we were able to isolate the effect of cellular health on early microvascular changes, rather than on advanced nephropathy. Second, by employing a comprehensive nonlinear exploration, we demonstrated that the protective effect of higher PhA in women persists independently of core metabolic confounders in a linear fashion, whereas men showed a newly identified J-shaped pattern. This sex-specific divergence has rarely been addressed in previous studies.
However, given the limited number of albuminuria cases relative to model complexity, the estimates may be sensitive to sampling variability and model specification. In the multivariable logistic models including 13 covariates (22 estimated model parameters in men and 21 in women), the EPV were approximately 4.9 in men and 5.9 in women, which was below the commonly recommended threshold of 10. Under these conditions, logistic models with quadratic terms may yield unstable curvatures at the distribution tails. To mitigate this potential instability, supplemental analyses were conducted using RCS modeling. The RCS approach, which provides flexible estimation of nonlinear associations, was consistent with a J-shaped relationship in men and a linear inverse association in women. Therefore, although replication in larger cohorts is warranted, these supplementary findings suggest that the observed sex-specific patterns remain robust across different statistical approaches.
This study has certain limitations. Owing to its cross-sectional design, the causal relationship between PhA and albuminuria cannot be determined. Although multivariate adjustments were performed, residual confounding could not be completely excluded. As the study population consisted only of Korean individuals, caution is required when generalizing these findings to other ethnic groups. In addition, UACR was measured using a spot urine sample, which may not fully reflect 24-hour urinary albumin excretion and can be affected by temporary physiological factors, such as hydration status or subclinical infections. Furthermore, the strict exclusion of individuals with diabetes or elevated serum creatinine levels limits the applicability of our findings to broader clinical populations. Although this design allowed us to observe early microvascular changes in a relatively healthy cohort, future studies including more diverse groups with established metabolic conditions are needed. Finally, a considerable number of participants were excluded owing to missing covariate data. Although missingness in the KNHANES is generally considered random, relying exclusively on complete-case analysis may introduce selection bias, potentially overrepresenting relatively healthier individuals. Future research using multiple imputation methods is warranted to confirm our findings and minimize potential biases.
Furthermore, the J-shaped association observed in men should be interpreted as hypothesis-generating. Because the suggested mechanisms, such as glomerular hyperfiltration and overnutrition, were not directly measured in this study, they remain exploratory rather than causal. It is also important to acknowledge that the nonlinear relationship in the male subgroup was statistically marginal (spline P=0.049) and was limited by the relatively low number of EPV (<10), with the upward limb of the curve supported by relatively few observations at the upper extreme of the PhA distribution. Therefore, these findings should be interpreted with caution and considered exploratory rather than conclusive until validated in larger prospective studies.
Clinically, PhA is a noninvasive, inexpensive, and reproducible parameter obtained from routine body composition analysis. Integrating PhA with conventional metabolic or renal markers may enhance the early detection of individuals at risk for microvascular dysfunction, particularly among those without diagnosed diabetes or renal disease. The use of PhA could also facilitate risk stratification in primary care, where more complex renal imaging or biomarkers are not readily available. In conclusion, wholebody PhA showed a sex-specific association with albuminuria in Korean adults, suggesting that it may warrant further investigation as a potential noninvasive marker of renal microvascular integrity. Further longitudinal studies are required to confirm these findings.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

Artificial intelligence (AI)-assisted language editing tools were used to improve the readability and grammatical accuracy of the manuscript. The authors reviewed and verified all AI-assisted modifications to ensure scientific integrity and accuracy of the content.

Funding

None.

Data availability

The data used in this study are publicly available from the Korea National Health and Nutrition Examination Survey (KNHANES), conducted by the Korea Disease Control and Prevention Agency (KDCA). The datasets can be accessed at https://knhanes.kdca.go.kr.

Author contribution

Conceptualization: DSP. Data curation: DSP. Formal analysis: DSP. Investigation: DSP. Methodology: all authors. Validation: DSP, YY. Writing–original draft: DSP. Writing–review & editing: all authors. Final approval of the manuscript: all authors.

Figure. 1.
Flow chart of the study population. KNHANES, Korea National Health and Nutrition Examination Survey.
kjfm-25-0305f1.jpg
Figure. 2.
Association between phase angle and the risk of albuminuria in men.
kjfm-25-0305f2.jpg
kjfm-25-0305f3.jpg
Table 1.
Baseline characteristics of the study participants according to sex and albuminuria status
Characteristic Men (n=1,495)
Women (n=1,788)
Non-albuminuria (n=1,388) Albuminuria (n=107) P-value Non-albuminuria (n=1,665) Albuminuria (n=123) P-value
Phase angle (°) 5.81±0.67 5.59±0.91 0.060 4.91±0.53 4.71±0.60 0.001
Age (y) 55.85±11.03 62.50±12.57 <0.001 57.48±11.13 62.12±11.87 <0.001
Height (cm) 170.72±6.34 167.61±6.34 <0.001 157.16±6.00 156.62±6.91 0.454
Weight (kg) 72.49±11.81 71.14±12.06 0.307 59.28±9.37 60.90±11.28 0.162
Body mass index (kg/m2) 24.81±3.36 25.26±3.59 0.262 23.98±3.43 24.76±3.84 0.055
Lifetime cigarette smoking history 0.795 0.381
 Non-smoker 267 (18.9) 18 (16.2) 1,508 (90.5) 113 (90.6)
 Less than 5 packs (100 cigarettes) 23 (1.8) 1 (2.5) 17 (1.3) 2 (3.0)
 5 packs (100 cigarettes) or more 1,098 (79.2) 88 (81.3) 140 (8.2) 8 (6.5)
Last year’s drinking frequency 0.051 0.010
 Non-drinker 51 (2.7) 6 (3.9) 294 (15.6) 27 (23.6)
 Did not drink at all in the last year 204 (13.2) 25 (21.3) 323 (19.7) 40 (31.8)
 Less than once a month 182 (14.1) 11 (12.6) 417 (26.3) 27 (19.0)
 About once a month 124 (8.6) 5 (4.9) 189 (10.9) 8 (5.9)
 2–4 times a month 358 (27.2) 17 (14.3) 260 (16.2) 13 (12.6)
 2–3 times a week 305 (22.9) 29 (30.5) 148 (9.0) 7 (6.1)
 4 or more times a week 164 (11.2) 14 (12.6) 34 (2.2) 1 (0.9)
Hypertension status <0.001 <0.001
 No hypertension 816 (62.2) 33 (27.7) 1,102 (68.2) 53 (46.1)
 Controlled hypertension 326 (21.4) 39 (35.2) 354 (19.8) 36 (26.8)
 Uncontrolled hypertension 246 (16.4) 35 (37.1) 209 (12.0) 34 (27.0)
Diabetes status 0.117 0.005
 Normal 666 (48.1) 37 (38.6) 931 (58.4) 53 (43.1)
 Prediabetes 722 (51.9) 70 (61.4) 734 (41.6) 70 (56.9)
HbA1c (%) 5.48±0.32 5.56±0.37 0.036 5.48±0.33 5.55±0.33 0.039
HDL cholesterol (mg/dL) 50.92±13.01 50.61±12.95 0.838 61.66±15.23 56.92±12.67 <0.001
Triglycerides (mg/dL) 165.10±134.49 151.40±94.35 0.204 112.91±62.10 122.10±62.79 0.148
LDL cholesterol (mg/dL) 121.49±35.93 109.75±33.23 0.002 121.37±36.72 120.46±33.95 0.785
Creatinine (mg/dL) 0.90±0.12 0.92±0.14 0.116 0.67±0.09 0.68±0.11 0.458
BUN (mg/dL) 14.87±3.82 15.98±4.22 0.015 14.18±3.88 15.09±4.56 0.055
High sensitivity C-reactive protein (mg/L) 1.42±3.95 2.72±8.55 0.079 1.24±3.35 1.64±4.34 0.365
Skeletal muscle mass index (kg/m2) 7.88±0.79 7.76±0.87 0.230 6.21±0.70 6.26±0.73 0.519
Urine albumin to creatinine ratio (mg/g) 6.18±4.82 225.85±551.10 0.001 7.71±5.22 103.22±136.72 <0.001

Values are presented as mean±standard deviation or unweighted number (survey-weighted %). P-values were obtained by the survey-weighted t-test for continuous variables and the survey-weighted chi-square test for categorical variables.

HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL cholesterol, low-density lipoprotein; BUN, blood urea nitrogen.

Table 2.
Association between phase angle and albuminuria in women
Variable Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
Phase angle (°) 0.49 (0.32–0.73) <0.001 0.47 (0.26–0.86) 0.015
Age (y) 1.04 (1.02–1.06) <0.001 1.00 (0.97–1.03) 0.976
Body mass index (kg/m2) 1.06 (1.00–1.13) 0.041 1.00 (0.91–1.10) 0.970
Lifetime cigarette smoking history
 Non-smoker Ref Ref
 Less than 5 packs (100 cigarettes) 2.35 (0.51–10.75) 0.270 2.85 (0.69–11.77) 0.148
 5 packs (100 cigarettes) or more 0.78 (0.35–1.76) 0.555 1.09 (0.46–2.59) 0.842
Last year’s drinking frequency
 Non-drinker Ref Ref
 Did not drink alcohol in the past year 1.07 (0.60–1.91) 0.825 1.26 (0.69–2.30) 0.443
 Less than once a month 0.48 (0.27–0.86) 0.013 0.63 (0.33–1.19) 0.157
 About once a month 0.36 (0.15–0.84) 0.018 0.52 (0.21–1.30) 0.163
 2–4 times a month 0.52 (0.24–1.11) 0.089 0.83 (0.35–1.93) 0.657
 2–3 times a week 0.45 (0.18–1.13) 0.088 0.72 (0.26–2.04) 0.542
 4 or more times a week 0.26 (0.03–2.05) 0.202 0.45 (0.06–3.6) 0.450
Hypertension status
 No hypertension Ref Ref
 Controlled hypertension 2.00 (1.24–3.23) 0.005 1.51 (0.84–2.72) 0.165
 Uncontrolled hypertension 3.33 (2.05–5.42) <0.001 2.50 (1.45–4.28) <0.001
HbA1c (%) 1.95 (1.05–3.62) 0.035 1.25 (0.66–2.39) 0.492
HDL cholesterol (mg/dL) 0.98 (0.96–0.99) <0.001 0.98 (0.97–1.00) 0.052
Triglycerides (mg/dL) 1.00 (1.00–1.00) 0.098 1.00 (1.00–1.00) 0.833
LDL cholesterol (mg/dL) 1.00 (0.99–1.00) 0.786 1.00 (1.00–1.01) 0.439
Creatinine (mg/dL) 2.60 (0.21–32.36) 0.455 2.81 (0.21–36.89) 0.431
BUN (mg/dL) 1.06 (1.00–1.11) 0.038 1.03 (0.98–1.10) 0.260
High sensitivity C-reactive protein (mg/L) 1.02 (0.99–1.06) 0.237 1.01 (0.98–1.05) 0.387
Skeletal muscle mass index (kg/m2) 1.1 (0.83–1.45) 0.514 1.35 (0.88–2.09) 0.172

Values are presented as OR (95% CI) and analyzed by survey-weighted multivariable logistic regression. Adjusted for age, body mass index, lifetime cigarette smoking history, last year’s drinking frequency, hypertension status, HbA1c, HDL cholesterol, triglycerides, LDL cholesterol, creatinine, BUN, high sensitivity C-reactive protein, skeletal muscle mass index.

OR, odds ratio; CI, confidence interval; Ref, reference; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BUN, blood urea nitrogen.

Table 3.
Association between phase angle and albuminuria in men
Variable Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
Phase angle (°) 0.65 (0.42–0.99) 0.046 0.05 (0.004–0.60) 0.019
Phase angle (°2) 0.97 (0.93–1.01) 0.101 1.34 (1.05–1.71) 0.018
Age (y) 1.05 (1.03–1.07) <0.001 1.04 (1.01–1.07) 0.014
Body mass index (kg/m2) 1.04 (0.97–1.11) 0.245 1.09 (0.97–1.21) 0.141
Lifetime cigarette smoking history
 Non-smoker Ref Ref
 Less than 5 packs (100 cigarettes) 1.61 (0.2–13.27) 0.655 2.22 (0.27–18.12) 0.454
 5 packs (100 cigarettes) or more 1.20 (0.67–2.17) 0.536 1.08 (0.56–2.07) 0.820
Last year’s drinking frequency
 Non-drinker Ref Ref
 Did not drink alcohol in the past year 1.13 (0.34–3.68) 0.843 1.32 (0.35–5.00) 0.680
 Less than once a month 0.62 (0.17–2.26) 0.469 1.10 (0.27–4.57) 0.894
 About once a month 0.40 (0.09–1.68) 0.209 0.69 (0.14–3.38) 0.645
 2–4 times a month 0.37 (0.11–1.18) 0.092 0.63 (0.16–2.49) 0.512
 2–3 times a week 0.93 (0.31–2.82) 0.898 1.75 (0.46–6.62) 0.407
 4 or more times a week 0.78 (0.22–2.73) 0.701 1.35 (0.30–6.03) 0.697
Hypertension status
 No hypertension Ref Ref
 Controlled hypertension 3.71 (2.11–6.51) <0.001 2.08 (1.15–3.76) 0.015
 Uncontrolled hypertension 5.07 (2.84–9.02) <0.001 3.82 (2.10–6.94) <0.001
HbA1c (%) 2.25 (1.08–4.71) 0.031 1.06 (0.52–2.16) 0.869
HDL cholesterol (mg/dL) 1.00 (0.98–1.02) 0.839 0.99 (0.97–1.01) 0.317
Triglycerides (mg/dL) 1.00 (1.00–1.00) 0.279 1.00 (1.00–1.00) 0.304
LDL cholesterol (mg/dL) 0.99 (0.98–1.00) 0.002 0.99 (0.99–1.00) 0.037
Creatinine (mg/dL) 5.37 (0.66–43.67) 0.116 2.83 (0.37–21.66) 0.316
BUN (mg/dL) 1.07 (1.02–1.13) 0.009 1.04 (0.98–1.11) 0.186
High sensitivity C-reactive protein (mg/L) 1.03 (1.01–1.06) 0.006 1.02 (0.99–1.06) 0.244
Skeletal muscle mass index (kg/m²) 0.83 (0.61–1.13) 0.232 0.77 (0.46–1.28) 0.312

Values are presented as OR (95% CI) and analyzed by survey-weighted multivariable logistic regression. Adjusted for age, body mass index, lifetime cigarette smoking history, last year’s drinking frequency, hypertension status, HbA1c, HDL cholesterol, triglycerides, LDL cholesterol, creatinine, BUN, high sensitivity C-reactive protein, skeletal muscle mass index.

OR, odds ratio; CI, confidence interval; Ref, reference; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BUN, blood urea nitrogen.

  • 1. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gomez JM, et al. Bioelectrical impedance analysis—part I: review of principles and methods. Clin Nutr 2004;23:1226-43.
  • 2. Lukaski HC. Biological indexes considered in the derivation of the bioelectrical impedance analysis. Am J Clin Nutr 1996;64:397S-404S.
  • 3. Baumgartner RN, Chumlea WC, Roche AF. Bioelectric impedance phase angle and body composition. Am J Clin Nutr 1988;48:16-23.
  • 4. Barbosa-Silva MC, Barros AJ. Bioelectrical impedance analysis in clinical practice: a new perspective on its use beyond body composition equations. Curr Opin Clin Nutr Metab Care 2005;8:311-7.
  • 5. Brunani A, Perna S, Soranna D, Rondanelli M, Zambon A, Bertoli S, et al. Body composition assessment using bioelectrical impedance analysis (BIA) in a wide cohort of patients affected with mild to severe obesity. Clin Nutr 2021;40:3973-81.
  • 6. Amano K, Bruera E, Hui D. Diagnostic and prognostic utility of phase angle in patients with cancer. Rev Endocr Metab Disord 2023;24:479-89.
  • 7. Ruiz-Margain A, Xie JJ, Roman-Calleja BM, Pauly M, White MG, Chapa-Ibarguengoitia M, et al. Phase angle from bioelectrical impedance for the assessment of sarcopenia in cirrhosis with or without ascites. Clin Gastroenterol Hepatol 2021;19:1941-9.
  • 8. Maddocks M, Kon SS, Jones SE, Canavan JL, Nolan CM, Higginson IJ, et al. Bioelectrical impedance phase angle relates to function, disease severity and prognosis in stable chronic obstructive pulmonary disease. Clin Nutr 2015;34:1245-50.
  • 9. Garlini LM, Alves FD, Ceretta LB, Perry IS, Souza GC, Clausell NO. Phase angle and mortality: a systematic review. Eur J Clin Nutr 2019;73:495-508.
  • 10. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6.
  • 11. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777-82.
  • 12. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992;340:319-23.
  • 13. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 2008;51:714-25.
  • 14. Jun MH, Kim S, Ku B, Cho J, Kim K, Yoo HR, et al. Glucose-independent segmental phase angles from multi-frequency bioimpedance analysis to discriminate diabetes mellitus. Sci Rep 2018;8:648.
  • 15. Liu L, He Y, Wang Y, Tao J, Wang J, Lu F, et al. Stronger associations of the phase angle than the TyG index with micro- and macrovascular complications in patients with type 2 diabetes. Lipids Health Dis 2025;24:125.
  • 16. Korea Disease Control and Prevention Agency. The Korea National Health and Nutrition Examination Survey (KNHANES), 2022–2023. Korea Disease Control and Prevention Agency; 2023-2024
  • 17. Roche Diagnostics. Creatinine Jaffé Gen.2 (CREJ2) package insert [Internet]. Roche Diagnostics; 2019 [cited 2025 Oct 22]. Available from: https://diagnostics.roche.com/global/en/products/lab/crej2-cps-000083.html
  • 18. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024;105:S117-314.
  • 19. Norman K, Stobaus N, Pirlich M, Bosy-Westphal A. Bioelectrical phase angle and impedance vector analysis: clinical relevance and applicability of impedance parameters. Clin Nutr 2012;31:854-61.
  • 20. da Silva BR, Gonzalez MC, Cereda E, Prado CM. Exploring the potential role of phase angle as a marker of oxidative stress: a narrative review. Nutrition 2022;93:111493.

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      Download Citation

      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:

      Include:

      Association between phase angle and albuminuria in Korean adults aged 40 years or older: a cross-sectional study of the 9th Korea National Health and Nutrition Examination Survey (2022–2023)
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Association between phase angle and albuminuria in Korean adults aged 40 years or older: a cross-sectional study of the 9th Korea National Health and Nutrition Examination Survey (2022–2023)
      Close

      Figure

      • 0
      • 1
      • 2
      Association between phase angle and albuminuria in Korean adults aged 40 years or older: a cross-sectional study of the 9th Korea National Health and Nutrition Examination Survey (2022–2023)
      Image Image Image
      Figure. 1. Flow chart of the study population. KNHANES, Korea National Health and Nutrition Examination Survey.
      Figure. 2. Association between phase angle and the risk of albuminuria in men.
      Graphical abstract
      Association between phase angle and albuminuria in Korean adults aged 40 years or older: a cross-sectional study of the 9th Korea National Health and Nutrition Examination Survey (2022–2023)
      Characteristic Men (n=1,495)
      Women (n=1,788)
      Non-albuminuria (n=1,388) Albuminuria (n=107) P-value Non-albuminuria (n=1,665) Albuminuria (n=123) P-value
      Phase angle (°) 5.81±0.67 5.59±0.91 0.060 4.91±0.53 4.71±0.60 0.001
      Age (y) 55.85±11.03 62.50±12.57 <0.001 57.48±11.13 62.12±11.87 <0.001
      Height (cm) 170.72±6.34 167.61±6.34 <0.001 157.16±6.00 156.62±6.91 0.454
      Weight (kg) 72.49±11.81 71.14±12.06 0.307 59.28±9.37 60.90±11.28 0.162
      Body mass index (kg/m2) 24.81±3.36 25.26±3.59 0.262 23.98±3.43 24.76±3.84 0.055
      Lifetime cigarette smoking history 0.795 0.381
       Non-smoker 267 (18.9) 18 (16.2) 1,508 (90.5) 113 (90.6)
       Less than 5 packs (100 cigarettes) 23 (1.8) 1 (2.5) 17 (1.3) 2 (3.0)
       5 packs (100 cigarettes) or more 1,098 (79.2) 88 (81.3) 140 (8.2) 8 (6.5)
      Last year’s drinking frequency 0.051 0.010
       Non-drinker 51 (2.7) 6 (3.9) 294 (15.6) 27 (23.6)
       Did not drink at all in the last year 204 (13.2) 25 (21.3) 323 (19.7) 40 (31.8)
       Less than once a month 182 (14.1) 11 (12.6) 417 (26.3) 27 (19.0)
       About once a month 124 (8.6) 5 (4.9) 189 (10.9) 8 (5.9)
       2–4 times a month 358 (27.2) 17 (14.3) 260 (16.2) 13 (12.6)
       2–3 times a week 305 (22.9) 29 (30.5) 148 (9.0) 7 (6.1)
       4 or more times a week 164 (11.2) 14 (12.6) 34 (2.2) 1 (0.9)
      Hypertension status <0.001 <0.001
       No hypertension 816 (62.2) 33 (27.7) 1,102 (68.2) 53 (46.1)
       Controlled hypertension 326 (21.4) 39 (35.2) 354 (19.8) 36 (26.8)
       Uncontrolled hypertension 246 (16.4) 35 (37.1) 209 (12.0) 34 (27.0)
      Diabetes status 0.117 0.005
       Normal 666 (48.1) 37 (38.6) 931 (58.4) 53 (43.1)
       Prediabetes 722 (51.9) 70 (61.4) 734 (41.6) 70 (56.9)
      HbA1c (%) 5.48±0.32 5.56±0.37 0.036 5.48±0.33 5.55±0.33 0.039
      HDL cholesterol (mg/dL) 50.92±13.01 50.61±12.95 0.838 61.66±15.23 56.92±12.67 <0.001
      Triglycerides (mg/dL) 165.10±134.49 151.40±94.35 0.204 112.91±62.10 122.10±62.79 0.148
      LDL cholesterol (mg/dL) 121.49±35.93 109.75±33.23 0.002 121.37±36.72 120.46±33.95 0.785
      Creatinine (mg/dL) 0.90±0.12 0.92±0.14 0.116 0.67±0.09 0.68±0.11 0.458
      BUN (mg/dL) 14.87±3.82 15.98±4.22 0.015 14.18±3.88 15.09±4.56 0.055
      High sensitivity C-reactive protein (mg/L) 1.42±3.95 2.72±8.55 0.079 1.24±3.35 1.64±4.34 0.365
      Skeletal muscle mass index (kg/m2) 7.88±0.79 7.76±0.87 0.230 6.21±0.70 6.26±0.73 0.519
      Urine albumin to creatinine ratio (mg/g) 6.18±4.82 225.85±551.10 0.001 7.71±5.22 103.22±136.72 <0.001
      Variable Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
      Phase angle (°) 0.49 (0.32–0.73) <0.001 0.47 (0.26–0.86) 0.015
      Age (y) 1.04 (1.02–1.06) <0.001 1.00 (0.97–1.03) 0.976
      Body mass index (kg/m2) 1.06 (1.00–1.13) 0.041 1.00 (0.91–1.10) 0.970
      Lifetime cigarette smoking history
       Non-smoker Ref Ref
       Less than 5 packs (100 cigarettes) 2.35 (0.51–10.75) 0.270 2.85 (0.69–11.77) 0.148
       5 packs (100 cigarettes) or more 0.78 (0.35–1.76) 0.555 1.09 (0.46–2.59) 0.842
      Last year’s drinking frequency
       Non-drinker Ref Ref
       Did not drink alcohol in the past year 1.07 (0.60–1.91) 0.825 1.26 (0.69–2.30) 0.443
       Less than once a month 0.48 (0.27–0.86) 0.013 0.63 (0.33–1.19) 0.157
       About once a month 0.36 (0.15–0.84) 0.018 0.52 (0.21–1.30) 0.163
       2–4 times a month 0.52 (0.24–1.11) 0.089 0.83 (0.35–1.93) 0.657
       2–3 times a week 0.45 (0.18–1.13) 0.088 0.72 (0.26–2.04) 0.542
       4 or more times a week 0.26 (0.03–2.05) 0.202 0.45 (0.06–3.6) 0.450
      Hypertension status
       No hypertension Ref Ref
       Controlled hypertension 2.00 (1.24–3.23) 0.005 1.51 (0.84–2.72) 0.165
       Uncontrolled hypertension 3.33 (2.05–5.42) <0.001 2.50 (1.45–4.28) <0.001
      HbA1c (%) 1.95 (1.05–3.62) 0.035 1.25 (0.66–2.39) 0.492
      HDL cholesterol (mg/dL) 0.98 (0.96–0.99) <0.001 0.98 (0.97–1.00) 0.052
      Triglycerides (mg/dL) 1.00 (1.00–1.00) 0.098 1.00 (1.00–1.00) 0.833
      LDL cholesterol (mg/dL) 1.00 (0.99–1.00) 0.786 1.00 (1.00–1.01) 0.439
      Creatinine (mg/dL) 2.60 (0.21–32.36) 0.455 2.81 (0.21–36.89) 0.431
      BUN (mg/dL) 1.06 (1.00–1.11) 0.038 1.03 (0.98–1.10) 0.260
      High sensitivity C-reactive protein (mg/L) 1.02 (0.99–1.06) 0.237 1.01 (0.98–1.05) 0.387
      Skeletal muscle mass index (kg/m2) 1.1 (0.83–1.45) 0.514 1.35 (0.88–2.09) 0.172
      Variable Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
      Phase angle (°) 0.65 (0.42–0.99) 0.046 0.05 (0.004–0.60) 0.019
      Phase angle (°2) 0.97 (0.93–1.01) 0.101 1.34 (1.05–1.71) 0.018
      Age (y) 1.05 (1.03–1.07) <0.001 1.04 (1.01–1.07) 0.014
      Body mass index (kg/m2) 1.04 (0.97–1.11) 0.245 1.09 (0.97–1.21) 0.141
      Lifetime cigarette smoking history
       Non-smoker Ref Ref
       Less than 5 packs (100 cigarettes) 1.61 (0.2–13.27) 0.655 2.22 (0.27–18.12) 0.454
       5 packs (100 cigarettes) or more 1.20 (0.67–2.17) 0.536 1.08 (0.56–2.07) 0.820
      Last year’s drinking frequency
       Non-drinker Ref Ref
       Did not drink alcohol in the past year 1.13 (0.34–3.68) 0.843 1.32 (0.35–5.00) 0.680
       Less than once a month 0.62 (0.17–2.26) 0.469 1.10 (0.27–4.57) 0.894
       About once a month 0.40 (0.09–1.68) 0.209 0.69 (0.14–3.38) 0.645
       2–4 times a month 0.37 (0.11–1.18) 0.092 0.63 (0.16–2.49) 0.512
       2–3 times a week 0.93 (0.31–2.82) 0.898 1.75 (0.46–6.62) 0.407
       4 or more times a week 0.78 (0.22–2.73) 0.701 1.35 (0.30–6.03) 0.697
      Hypertension status
       No hypertension Ref Ref
       Controlled hypertension 3.71 (2.11–6.51) <0.001 2.08 (1.15–3.76) 0.015
       Uncontrolled hypertension 5.07 (2.84–9.02) <0.001 3.82 (2.10–6.94) <0.001
      HbA1c (%) 2.25 (1.08–4.71) 0.031 1.06 (0.52–2.16) 0.869
      HDL cholesterol (mg/dL) 1.00 (0.98–1.02) 0.839 0.99 (0.97–1.01) 0.317
      Triglycerides (mg/dL) 1.00 (1.00–1.00) 0.279 1.00 (1.00–1.00) 0.304
      LDL cholesterol (mg/dL) 0.99 (0.98–1.00) 0.002 0.99 (0.99–1.00) 0.037
      Creatinine (mg/dL) 5.37 (0.66–43.67) 0.116 2.83 (0.37–21.66) 0.316
      BUN (mg/dL) 1.07 (1.02–1.13) 0.009 1.04 (0.98–1.11) 0.186
      High sensitivity C-reactive protein (mg/L) 1.03 (1.01–1.06) 0.006 1.02 (0.99–1.06) 0.244
      Skeletal muscle mass index (kg/m²) 0.83 (0.61–1.13) 0.232 0.77 (0.46–1.28) 0.312
      Table 1. Baseline characteristics of the study participants according to sex and albuminuria status

      Values are presented as mean±standard deviation or unweighted number (survey-weighted %). P-values were obtained by the survey-weighted t-test for continuous variables and the survey-weighted chi-square test for categorical variables.

      HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL cholesterol, low-density lipoprotein; BUN, blood urea nitrogen.

      Table 2. Association between phase angle and albuminuria in women

      Values are presented as OR (95% CI) and analyzed by survey-weighted multivariable logistic regression. Adjusted for age, body mass index, lifetime cigarette smoking history, last year’s drinking frequency, hypertension status, HbA1c, HDL cholesterol, triglycerides, LDL cholesterol, creatinine, BUN, high sensitivity C-reactive protein, skeletal muscle mass index.

      OR, odds ratio; CI, confidence interval; Ref, reference; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BUN, blood urea nitrogen.

      Table 3. Association between phase angle and albuminuria in men

      Values are presented as OR (95% CI) and analyzed by survey-weighted multivariable logistic regression. Adjusted for age, body mass index, lifetime cigarette smoking history, last year’s drinking frequency, hypertension status, HbA1c, HDL cholesterol, triglycerides, LDL cholesterol, creatinine, BUN, high sensitivity C-reactive protein, skeletal muscle mass index.

      OR, odds ratio; CI, confidence interval; Ref, reference; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BUN, blood urea nitrogen.

      TOP